search
Back to results

Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study

Primary Purpose

Obesity, Diabetes Mellitus, Type 2, Abnormal Glucose Metabolism

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Assignment of a Lay Patient Partner
Sponsored by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Type 2 Diabetes Mellitus, Adolescents, Pediatric, Patient Partner, Buddy, Obesity, Type 2 Diabetes

Eligibility Criteria

12 Years - 20 Years (Child, Adult)All SexesDoes not accept healthy volunteers
  • INCLUSION CRITERIA:

Any patient with type 2 diabetes mellitus as documented by his or her primary physician

  1. Age 12-20 years at enrollment
  2. Most recent HbA1c greater than or equal to 7%

EXCLUSION CRITERIA:

  1. Significant comorbidity that, in the opinion of the investigators, may limit adequate study participation
  2. Significant psychiatric or cognitive disorder, or communication difficulty that will, in the opinion of the investigators, limit the subject's ability to interact with the patient assistant or may present a danger to the patient assistant; patients with current suicidal or homicidal ideation, history of arrest for violent behavior, or history of school suspension/expulsion for violent behavior will be excluded.
  3. Pregnancy or intention to become pregnant within 6 months

Sites / Locations

  • Childrens National Medical Center
  • National Institutes of Health Clinical Center, 9000 Rockville Pike

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Active Comparator

Arm Label

Group A

Group B

Arm Description

Buddy Group - Individuals with type 2 diabetes receive conventional diabetes treatment and are assigned a patient partner (Buddy)

Individuals receive conventional treatment for type 2 diabetes

Outcomes

Primary Outcome Measures

To evaluate the effect of a minimally invasive intervention (the buddy system) on hemoglobin A1c levels in adolescents with T2DM.

Secondary Outcome Measures

To assess changes between groups in body weight, number of home glucose monitor checks, compliance with medications, adherence to visit schedule, and psychological well-being.

Full Information

First Posted
November 3, 2009
Last Updated
December 14, 2019
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT01007266
Brief Title
Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study
Official Title
Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 14, 2016
Overall Recruitment Status
Completed
Study Start Date
October 9, 2009 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
January 24, 2013 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

5. Study Description

Brief Summary
Background: Type 2 diabetes mellitus (T2DM) is becoming more common among youth, particularly in minority populations. Few drug treatments are approved for T2DM in adolescents, and behavioral and lifestyle factors may contribute to their difficulties in following strict treatment regimens. It is unknown whether a minimally invasive patient partner ( buddy ) program, which has been developed to help improve diabetes control and quality of life, will be successful in a population of pediatric patients with T2DM. Objectives: To evaluate the effect of a minimally invasive intervention (being assigned a patient partner, or buddy ) on blood sugar levels in adolescents with T2DM. To assess changes between groups in body weight, number of home glucose monitor checks, compliance with medications, adherence to visit schedule, and psychological well-being. Eligibility: - Adolescents and young adults between 12 and 20 years of age who have been diagnosed with type 2 diabetes and whose blood glucose control needs improvement. Design: Participants will be divided by chance into two groups: in one group, participants will have a buddy and receive standard care; while in the other group, participants will receive standard care alone. The buddy is not a health care professional and is not authorized to provide any medical advice. Participants will be followed in the study for a total of 6 months. All study participants will receive standard treatment for T2DM. All patients will be asked to fill out a screening questionnaire (on paper or online) at the beginning of the study and a quality of life and eating behaviors questionnaire at the beginning and at the end of the study. These forms will include questions on medical history, emotions, well-being, and eating habits. Participants in both groups will have one diabetes clinic visit at the NIH Clinical Center or at Children s National Medical Center (CNMC) at the beginning of the study and two follow-up visits at the NIH or CNMC approximately 3 months apart. All visits include a physical examination, detailed medical history, and laboratory testing which is part of routine care for diabetes. Participants assigned to the buddy group will receive phone or online messages from the buddy once a week and will meet with the buddy once a month for less than 1 hour. The purpose of the in-person visit is to get to know each other better outside the usual hospital or clinic environment. The visits should take place at home, but may also take place elsewhere, for example, at schools, cafes, or libraries chosen by both the participant and the buddy. These face-to-face meetings may also take place at NIH or at CNMC if this is more convenient.
Detailed Description
Background Type 2 diabetes mellitus (T2DM) is becoming increasingly prevalent among youth, particularly in minority populations. Few pharmacologic agents are approved for the treatment of T2DM in adolescents, and behavioral and lifestyle factors may contribute to adolescents difficulty adhering to treatment regimens. A minimally-invasive buddy-intervention (to help improve diabetes control and to foster improvement in quality of life) has not been systematically evaluated in a population of pediatric patients with T2DM. Objectives To evaluate the effect of a minimally invasive intervention the buddy on hemoglobin A1c (HbA1c) levels in adolescents with T2DM. To assess changes between groups in body weight, number of home glucose monitor checks, compliance with medications, adherence to visit schedule, and psychological well-being. Methods Patients will be randomized to conventional treatment versus interventional group (buddy arm), and will be followed for 6 months. During this period, all patients should undergo two visits including laboratory testing (HbA1c) approximately 3 months apart. Those in the buddy arm will have weekly phone or online contact and once-monthly home visits from the buddy (a volunteer patient partner), with the use of systematic questionnaires and a secure database for data collection and maintenance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Diabetes Mellitus, Type 2, Abnormal Glucose Metabolism, Type 2 Diabetes
Keywords
Type 2 Diabetes Mellitus, Adolescents, Pediatric, Patient Partner, Buddy, Obesity, Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group A
Arm Type
Other
Arm Description
Buddy Group - Individuals with type 2 diabetes receive conventional diabetes treatment and are assigned a patient partner (Buddy)
Arm Title
Group B
Arm Type
Active Comparator
Arm Description
Individuals receive conventional treatment for type 2 diabetes
Intervention Type
Behavioral
Intervention Name(s)
Assignment of a Lay Patient Partner
Primary Outcome Measure Information:
Title
To evaluate the effect of a minimally invasive intervention (the buddy system) on hemoglobin A1c levels in adolescents with T2DM.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
To assess changes between groups in body weight, number of home glucose monitor checks, compliance with medications, adherence to visit schedule, and psychological well-being.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION CRITERIA: Any patient with type 2 diabetes mellitus as documented by his or her primary physician Age 12-20 years at enrollment Most recent HbA1c greater than or equal to 7% EXCLUSION CRITERIA: Significant comorbidity that, in the opinion of the investigators, may limit adequate study participation Significant psychiatric or cognitive disorder, or communication difficulty that will, in the opinion of the investigators, limit the subject's ability to interact with the patient assistant or may present a danger to the patient assistant; patients with current suicidal or homicidal ideation, history of arrest for violent behavior, or history of school suspension/expulsion for violent behavior will be excluded. Pregnancy or intention to become pregnant within 6 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kristina I Rother, M.D.
Organizational Affiliation
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Childrens National Medical Center
City
Washington
State/Province
District of Columbia
Country
United States
Facility Name
National Institutes of Health Clinical Center, 9000 Rockville Pike
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
9135953
Citation
Yokoyama H, Okudaira M, Otani T, Takaike H, Miura J, Saeki A, Uchigata Y, Omori Y. Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care. 1997 May;20(5):844-7. doi: 10.2337/diacare.20.5.844.
Results Reference
background
PubMed Identifier
10358675
Citation
Krieger J, Collier C, Song L, Martin D. Linking community-based blood pressure measurement to clinical care: a randomized controlled trial of outreach and tracking by community health workers. Am J Public Health. 1999 Jun;89(6):856-61. doi: 10.2105/ajph.89.6.856.
Results Reference
background
PubMed Identifier
16651496
Citation
Duncan GE. Prevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and Nutrition Examination Survey, 1999-2002. Arch Pediatr Adolesc Med. 2006 May;160(5):523-8. doi: 10.1001/archpedi.160.5.523.
Results Reference
background

Learn more about this trial

Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study

We'll reach out to this number within 24 hrs